Craving & Decision-Making
Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · May 28, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Craving & Decision-Making," is looking at how strong desires, or cravings, can affect the choices people make. Researchers want to understand how craving for things like opioids or specific snacks influences how much someone is willing to pay for everyday items or food. The study involves tasks where participants will decide how much they value various items while experiencing cravings. By examining brain activity during these decisions, the researchers hope to uncover the connections between craving and how people assign value to different choices.
To participate in this study, you must be at least 18 years old and able to read and understand the study materials. If you have a diagnosis of opioid use disorder (OUD), you should also be receiving treatment for it. The study is open to all genders, and participants will be required to complete tasks that involve decision-making while their brain activity is monitored through an MRI scan. It's important to note that certain health conditions or medications may exclude you from participating. Overall, this trial aims to shed light on the complex relationship between craving and decision-making, which could help improve treatment approaches for people with substance use issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • At least 18 years of age
- • Willingness to follow study requirements, as evidenced by an ability to provide written informed consent and read, understand, and complete the study procedures
- • Minimum of 6th grade reading level
- Additional inclusion criteria for participants with OUD:
- • Primary diagnosis of OUD encompassing heroin and/or painkiller use
- • Receiving medications for OUD treatment on an outpatient basis
- • At least 12-month history of opioid use
- Exclusion Criteria:
- • Unable to speak or read English
- • Active psychosis or mania
- • Current or past schizophrenia diagnosis
- • History of intellectual disability or developmental or neurological disorder, seizures or epilepsy, or loss consciousness lasting more than 30 minutes
- • Severe medical conditions requiring hospitalization or that, in the opinion of the study staff could compromise study participation
- • MRI contraindications (claustrophobia, nonremovable piercings, certain metal in the body etc.) or pregnancy
- Additional exclusion criteria for community control participants:
- • Positive urine drug screen
- • Current or past problematic substance use other than nicotine, and alcohol abuse confined to college or military service
- • Current or past bipolar disorder diagnosis
- • Use of central nervous system medications within the past 6 weeks (e.g., antidepressants, Ritalin)
About Rutgers, The State University Of New Jersey
Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Piscataway, New Jersey, United States
Patients applied
Trial Officials
Anna Konova, PhD
Principal Investigator
Rutgers, The State University of New Jersey
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported